Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A range of lymphoproliferative diseases characterized by uncontrolled proliferation of B cells, T cells, or NK cells infected with Epstein-Barr virus. Depending on host immunity and viral factors, viral persistence in host cells can induce lymphoproliferation with a diverse clinical spectrum ranging from simple reactive hyperplasia to aggressive lymphoma/leukemia with unique clinical and pathological presentations.
Biomarker and diagnostic research for Epstein-Barr virus-associated lymphoproliferative disorder has been reported in the published literature.
No clinical trials have been registered for Epstein-Barr virus-associated lymphoproliferative disorder.
139 publications have been identified in PubMed for Epstein-Barr virus-associated lymphoproliferative disorder. Research spans Review / Meta-Analysis (32%), Basic Science / Preclinical (29%), and Case Report / Case Series (14%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 44 | 32% |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 2:44 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Epstein-Barr virus-associated lymphoproliferative disorder
Laboratory research |
41 |
29% |
Patient case studies | 20 | 14% |
Disease patterns and progression | 12 | 9% |
New treatment approaches | 10 | 7% |
Testing and diagnosis research | 7 | 5% |
Clinical study results | 5 | 4% |
Xu Y (2026). [PMID: 42198896](https://pubmed.ncbi.nlm.nih.gov/42198896/). *J Med Virol*. [Diagnostic / Biomarker]
Obeagu EI (2026). [PMID: 41578561](https://pubmed.ncbi.nlm.nih.gov/41578561/). *Medicine (Baltimore)*. [Review / Meta-Analysis]
Burner DN (2026). [PMID: 42198688](https://pubmed.ncbi.nlm.nih.gov/42198688/). *Viruses*. [Case Report / Case Series]
Rattin J (2026). [PMID: 42066597](https://pubmed.ncbi.nlm.nih.gov/42066597/). *Ann Diagn Pathol*. [Case Report / Case Series]
Yeo YY (2026). [PMID: 41923627](https://pubmed.ncbi.nlm.nih.gov/41923627/). *Cell Rep Med*. [Basic Science / Preclinical]
Popov VM (2026). [PMID: 42084518](https://pubmed.ncbi.nlm.nih.gov/42084518/). *Oncology (Williston Park)*. [Case Report / Case Series]
Oikawa M (2026). [PMID: 41674158](https://pubmed.ncbi.nlm.nih.gov/41674158/). *Modern rheumatology case reports*. [Case Report / Case Series]
Hasegawa T (2026). [PMID: 41762376](https://pubmed.ncbi.nlm.nih.gov/41762376/). *Clin J Gastroenterol*. [Case Report / Case Series]
Buchner AM (2026). [PMID: 41549853](https://pubmed.ncbi.nlm.nih.gov/41549853/). *Eur J Gastroenterol Hepatol*. [Epidemiology / Natural History]
Huang HH (2026). [PMID: 41576253](https://pubmed.ncbi.nlm.nih.gov/41576253/). *Ann Plast Surg*. [Case Report / Case Series]
AI-curated news mentioning Epstein-Barr virus-associated lymphoproliferative disorder
Updated Jul 28, 2026
A new study discusses postoperative adjuvant treatment decisions for early Epstein-Barr virus-associated gastric cancer. This research may influence treatment protocols and improve patient outcomes in this specific cancer type.
A case study details a 21-year-old man suffering from anemia and gastrointestinal bleeding due to jejunal EBV-associated T/natural killer-cell lymphoproliferative disorder. This highlights the clinical implications of this rare lymphoproliferative disorder linked to Epstein-Barr virus.